ArticleCanadian journal of respiratory therapy : CJRT = Revue canadienne de la therapie respiratoire : RCTR2020
Association of COVID-19 and other viral infections with interstitial lung diseases, pulmonary fibrosis, and pulmonary hypertension: A narrative review.
Article in Canadian journal of respiratory therapy : CJRT = Revue canadienne de la therapie respiratoire : RCTR, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Effects of Exercise Training on Cardiopulmonary Function and Quality of Life in Elderly Patients with Pulmonary Fibrosis: A Meta-Analysis.International journal of environmental research and public health · 2021Pooled it
- Development and Validation of a CT-based Deep Transfer Learning Radiomic Model for Predicting Post-COVID-19 Pulmonary FibrosisCurrent medical imaging · 2026Article
- An Autopsy for Persistent Coronavirus Disease 2019 Pneumonia during Follicular Lymphoma Treatment.Internal medicine (Tokyo, Japan) · 2025Article
- A Narrative Review of Key Risk Factors for Severe Illness Following SARS-CoV-2, Influenza Virus, and Respiratory Syncytial Virus Infection.Infectious diseases and therapy · 2025Review
- COVID-19 and Comorbidities: What Has Been Unveiled by Metabolomics?Metabolites · 2024Review
- Interstitial lung changes and persistent COVID-19 in a patient with follicular lymphoma: A case report.Respirology case reports · 2024Article
- U-Net-based computed tomography quantification of viral pneumonia can predict fibrotic interstitial lung abnormalities at 3-month follow-up.Frontiers in medicine · 2024Article
- Clinicopathological Outlines of Post-COVID-19 Pulmonary Fibrosis Compared with Idiopathic Pulmonary Fibrosis.Biomedicines · 2023Review
- The Evolving Phenotypes of Cardiovascular Disease during COVID-19 Pandemic.Cardiovascular drugs and therapy · 2023Review
- Cardiovascular, Pulmonary, and Neuropsychiatric Short- and Long-Term Complications of COVID-19.Cells · 2022Review
- The Role of DNA Damage and Repair in Idiopathic Pulmonary Fibrosis.Antioxidants (Basel, Switzerland) · 2022Review
- New grading system for post-COVID-19 pulmonary fibrosis based on computed tomography findings.Medicine · 2022Article
- Tailored Post-Acute Care Coordination for Survivors of Moderate to Severe COVID-19 Infection.Journal of the American Medical Directors Association · 2022Article
- Seven days treatment with the angiotensin II type 2 receptor agonist C21 in hospitalized COVID-19 patients; a placebo-controlled randomised multi-centre double-blind phase 2 trial.EClinicalMedicine · 2021Article
- Role of JAK/STAT in Interstitial Lung Diseases; Molecular and Cellular Mechanisms.International journal of molecular sciences · 2021Review
- Lungs after COVID-19: Evolving Knowledge of Post-COVID-19 Interstitial Lung Disease.Annals of the American Thoracic Society · 2021Article
- Interrelation Between Fibroblasts and T Cells in Fibrosing Interstitial Lung Diseases.Frontiers in immunology · 2021Review
- Perpetually Positive: Post-COVID Interstitial Lung Disease in an Immunocompromised Patient With Diffuse Large B-cell Lymphoma.Journal of investigative medicine high impact case reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInterstitial lung diseases (ILDs) include a broad range of diffuse parenchymal lung disorders and are characterized by diffuse parenchymal lung abnormalities leading to irreversible fibrosis. ILDs are correlated with the occurrence of pulmonary fibrosis (PF), which generally also results in pulmonary hypertension (PH). Interferons, secreted in larger amounts during viral infections, are an important possible risk factor contributing to this outcome.
aimsIn this narrative review, the role of 10 different viral infections on the generation/development of ILDs and their outcomes are described in detail. The aim of this review is to determine the probable risk that COVID-19 and other viral infections pose in the post-infection development of ILDs, PF, and PH.
methodsSearches in PubMed (Medline), Google Scholar, Web of Science (ISI, Researcher ID, Publons), ResearchGate, Scopus, and secondary sources yielded 134 studies. After exclusion criteria, 92 studies containing the terms "Coronavirus" (COVID-19), "Interstitial Lung Diseases," "Pulmonary Fibrosis," "Pulmonary Hypertension" and "viral infections" were selected for inclusion. Selected articles were read with a focus on the roles of the 10 commonly studied viral infections on generation/intensification of ILDs and classified according to their dominant effect on the respiratory system, with a focus on each infection's effects on parenchyma of the lungs and generation and/or intensification of ILDs.
resultsThis review found that ILDs, PF, and PH can occur after a COVID-19 viral infection. Similar results are also seen in post-infection cases of other viral infections, including Epstein-Barr virus, Cytomegalovirus, Human herpesvirus-8, adenovirus, Hepatitis C, Torque-Teno (Transfusion-Transmitted) Virus, Human Immunodeficiency Virus, Severe Acute Respiratory Syndrome, and Middle East Respiratory Syndrome.
conclusionResults of current studies show probable possibility for generation and/or intensification of ILDs in COVID-19 infected patients like other studied viruses. Studies on determination of the actual prevalence of ILD, PF and PH in post-COVID-19 infected patients, follow-up studies on the prevention of ILDs in recovered COVID-19 patients, and meta-analyzed studies on pulmonary outcomes of pandemic corona viruses are strongly recommended as topics for future studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.